Methamphetamine effects on blood-brain barrier structure and function
- Department of Neurosciences, University of Toledo College of Medicine, Toledo, OH, USA
Methamphetamine (Meth) is a widely abuse psychostimulant. Traditionally, studies have focused on the neurotoxic effects of Meth on monoaminergic neurotransmitter terminals. Recently, both in vitro and in vivo studies have investigated the effects of Meth on the BBB and found that Meth produces a decrease in BBB structural proteins and an increase in BBB permeability to various molecules. Moreover, preclinical studies are validated by clinical studies in which human Meth users have increased concentrations of toxins in the brain. Therefore, this review will focus on the structural and functional disruption of the BBB caused by Meth and the mechanisms that contribute to Meth-induced BBB disruption. The review will reveal that the mechanisms by which Meth damages dopamine and serotonin terminals are similar to the mechanisms by which the blood-brain barrier (BBB) is damaged. Furthermore, this review will cover the factors that are known to potentiate the effects of Meth (McCann et al., 1998) on the BBB, such as stress and HIV, both of which are co-morbid conditions associated with Meth abuse. Overall, the goal of this review is to demonstrate that the scope of damage produced by Meth goes beyond damage to monoaminergic neurotransmitter systems to include BBB disruption as well as provide a rationale for investigating therapeutics to treat Meth-induced BBB disruption. Since a breach of the BBB can have a multitude of consequences, therapies directed toward the treatment of BBB disruption may help to ameliorate the long-term neurodegeneration and cognitive deficits produced by Meth and possibly even Meth addiction.
Methamphetamine (Meth) is a widely abused psychostimulant that causes long-term monoamine neurotransmitter depletions. The well-established mechanisms responsible for Meth-induced damage to monoaminergic terminals are not selective but likely target other cell types and tissues as well. In this review, the focus will be on the effects of Meth and comorbid factors on blood-brain barrier (BBB) structure and function and how the mechanisms of Meth-induced monoaminergic damage can also contribute to BBB damage. In addition, potential consequences of Meth-induced BBB disruption and the importance of further research regarding Meth-induced BBB disruption will be discussed.
Meth produces long-term neuronal damage in humans, non-human primates and rodents. Positron emission tomography (PET) and proton magnetic resonance spectroscopy (MRS) studies in abstinent human Meth users indicate damage to the dopaminergic and serotonergic systems, marked by decreases in the dopamine (DA) and serotonin (5-HT) transporters, DAT (McCann et al., 1998; Volkow et al., 2001a,b) and SERT (Sekine et al., 2006), which can last up to 3 years after the end of Meth use. PET and MRI observations in abstinent Meth users are substantiated by studies of human postmortem brain tissue and rodent studies. Postmortem studies of brains from chronic Meth users as well as rodents exposed to Meth, illustrate decreases in DA, tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), vesicular monoamine transporter -2 (VMAT-2), DAT and SERT, in areas highly innervated by DA and 5-HT terminals (Hotchkiss and Gibb, 1980; Ricaurte et al., 1980; Wagner et al., 1980; Wilson et al., 1996; Cass and Manning, 1999; Moszczynska et al., 2004; Eyerman and Yamamoto, 2007; Kitamura et al., 2007; Kish et al., 2009).
While the traditional belief is that Meth selectively damages DA and 5-HT axon terminals, more recent studies suggest that Meth produces more widespread damage. Meth users have decreases in the neuronal marker, N-acetylaspartate (Ernst et al., 2000; Chang et al., 2005), which is a more general indication of injury. In addition, rodent studies have shown that Meth produces damage to cell bodies evidenced by increased caspase-mediated proteolysis and TUNEL staining in the striatum and hippocampus (Schmued and Bowyer, 1997; Deng et al., 2001; Warren et al., 2005). Moreover, a study by Zhu et al. (2006) observed that parvalbumin-positive γ-aminobutyric acid (GABA) interneurons and cholinergic interneurons in the striatum undergo apoptosis after a single administration of 30 mg/kg Meth to mice. Meth binge treatment also decreases the number of glutamatergic neurons in the somatosensory cortex (Pu et al., 1996). Therefore, the toxic effects of Meth extend beyond dopaminergic and serotonergic terminals but the mechanisms mediating those effects remain to be determined.
Mechanisms of Monoamine Damage
Many studies have investigated the mechanisms responsible for monoamine neurotransmitter damage caused by Meth. Those mechanisms include hyperthermia, neurotransmitter release, oxidative stress, mitochondrial dysfunction and inflammation.
Hyperthermia is an acute effect of Meth and appears necessary but is not sufficient to cause monoaminergic damage (Bowyer et al., 1992, 1994; Xie et al., 2000). This is evidenced by the fact that Meth-induced monoaminergic terminal damage is not observed in rodents that are placed in a setting with low ambient temperature and do not experience Meth-induced hyperthermia (Bowyer et al., 1992, 1994). Furthermore, pharmacological interventions that attenuate hyperthermia also attenuate Meth-induced monoaminergic damage. For example, antagonism of NMDA receptors using MK-801 or D1 or D2 dopaminergic receptors using SCH23390 and haloperidol, respectively, prevents Meth-induced hyperthermia and toxicity (Bowyer et al., 1994; Albers and Sonsalla, 1995). In contrast, several studies suggest that hyperthermia is not the sole mechanism since pharmacological interventions that do not alter hyperthermia will attenuate Meth toxicity (Itzhak et al., 2000; Ladenheim et al., 2000; Callahan et al., 2001; Sanchez et al., 2003).
Neurotransmitter release is a well-known acute effect of Meth. Meth increases extracellular concentrations of DA and glutamate (Raiteri et al., 1979; Mark et al., 2004). A consequence of these increases in cytosolic DA and extracellular glutamate is the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). MAO metabolism of DA to DOPAC as well as autoxidation of DA results in the formation of ROS (Graham et al., 1978; Spina and Cohen, 1989; Hastings et al., 1996; Alper et al., 1999; Lavoie and Hastings, 1999). On the other hand, increased extracellular glutamate activates its calcium permeable receptors and results in the activation of nitric oxide synthase (NOS) (Dawson et al., 1991) and subsequent reactive nitrogen species (RNS) (Obata, 2002).
The role of ROS and RNS in Meth-induced monoaminergic terminal damage is well-established. Antioxidants such as N-acetyl-L-cysteine, ascorbic acid and vitamin E and NOS inhibitors attenuate Meth-induced striatal DA and 5-HT depletions (Wagner et al., 1985; De Vito and Wagner, 1989; Abekawa et al., 1996; Imam et al., 2001a; Fukami et al., 2004; Eyerman and Yamamoto, 2007). In addition, administration of Meth to mice overexpressing copper/zinc superoxide dismutase (Cu/ZnSOD) or manganese superoxide dismutase (MnSOD), enzymes responsible for eliminating superoxide radicals, or neuronal nitric oxide synthase (nNOS) knockout mice does not result in striatal damage (Cadet et al., 1994a,b; Hirata et al., 1995; Itzhak et al., 1998; Maragos et al., 2000; Imam et al., 2001b). In contrast, an SOD inhibitor enhances Meth-induced DA and 5-HT depletions in the rat striatum (De Vito and Wagner, 1989). Collectively, these data support the role of oxidative stress in Meth-induced neurotoxicity.
Excess extracellular glutamate can damage monoamine terminals independent of nNOS. Upon activation of its calcium permeable NMDA or AMPA receptors, glutamate results in an increase in intracellular calcium, which in turn activates calcium dependent enzymes and ultimately leads to cellular damage. In fact, Meth administration results in calpain-mediated spectrin proteolysis, which is associated with damage to striatal DA terminals (Staszewski and Yamamoto, 2006). In addition, it has been shown that inhibition of glutamate release from corticostriatal pathways or blockade of glutamate receptors prevents Meth-induced damage to striatal DA terminals (Sonsalla et al., 1991; Stephans and Yamamoto, 1994; Battaglia et al., 2002; Mark et al., 2004). Therefore, multiple studies support the role of excitotoxicity in Meth-induced monoaminergic terminal damage.
More recently, it was observed that Meth damages the liver, which can release factors known to mediate brain damage as in the case of hepatic encephalopathy. Binge Meth administration results in liver damage and consequent increases in circulating ammonia (Halpin and Yamamoto, 2012). Brain concentrations of ammonia are also elevated after Meth exposure and contribute to Meth-induced increases in extracellular glutamate (Halpin and Yamamoto, 2012; Halpin et al., 2014). Intrastriatal injection of the combination of Meth and ammonia produce decreases in monoamine tissue content that are prevented by the glutamate receptor AMPA antagonist, GYKI 52466 (Halpin and Yamamoto, 2012). In addition, treatment with an ammonia scavenger, lactulose, that is limited to the gut and does not enter the brain, attenuates Meth-induced monoamine depletions (Halpin and Yamamoto, 2012). These data together provide evidence that Meth not only damages the brain, but also damages peripheral organs, and the resulting increases in circulating ammonia contributes to Meth-induced monoaminergic damage in a glutamate dependent manner.
Mitochondrial dysfunction or bioenergetic stress is another mechanism by which Meth causes toxicity. Meth results in a depletion of ATP (Chan et al., 1994) and inhibits complex II of the electron transport chain (Brown et al., 2005) whereas treatment with the mitochondrial complex substrates, decylubiquinone or nicotinamide, after Meth treatment, attenuates Meth-induced striatal DA depletions (Stephans et al., 1998). Thus, a bioenergetic compromise and mitochondrial dysfunction play a role in Meth-induced monoaminergic terminal damage.
Less clear is the direct role of inflammation in Meth-induced monoaminergic terminal damage. Meth-induced monoaminergic damage is associated with neuroinflammation in humans and rodents. Recent PET scans of human Meth users indicate prominent microglial activation (Chang et al., 2002; Sekine et al., 2008) and chronic Meth users present with increased plasma cytokines and chemokines (Loftis et al., 2011). These observations are substantiated by preclinical studies that also observe glial activation (Escubedo et al., 1998; Lavoie et al., 2004; Thomas et al., 2004a,c) and increases in inflammatory mediators (Yamaguchi et al., 1991; Flora et al., 2002; Thomas et al., 2004b; Goncalves et al., 2008; Loftis et al., 2011) in various brain regions, including the hippocampus and striatum after Meth administration. Microglial activation is closely associated with Meth-induced monoaminergic damage and lack of microglial activation is typically associated with lack of monoaminergic damage (Lavoie et al., 2004; Thomas et al., 2004a,c). In addition, indomethacin attenuates microglial activation and decreases in beta III tubulin expression produced by Meth but monoaminergic depletions were not investigated (Goncalves et al., 2010). In contrast, microglial activation may be a consequence of Meth-induced damage, not limited to monoaminergic damage. The role of individual cytokines is less clear. Meth-induced monoaminergic terminal damage is prevented in IL-6 knockout mice (Ladenheim et al., 2000), suggesting a harmful role for IL-6. In contrast, intrastriatal injections of TNF-α attenuate rather than enhance Meth-induced decreases in DA and tyrosine hydroxylase (Nakajima et al., 2004), suggesting a protective role for TNF-α. Furthermore, Meth-induced DA depletions are still observed in TNF-α and COX-2 knockout mice, when Meth-induced hyperthermia is maintained (Nakajima et al., 2004; Thomas and Kuhn, 2005). Therefore, there is a tenuous relationship between inflammation and monoaminergic damage produced by Meth and the role of neuroinflammation in Meth-induced monoaminergic terminal damage warrants further investigation.
In summary, there is clear evidence that the acute effects of Meth, including hyperthermia, oxidative stress, excitotoxicity and mitochondrial dysfunction play a role in Meth-induced monoamine terminal damage. Research has focused primarily on the dopaminergic and serotonergic systems because of the direct pharmacological actions of Meth at DAT and SERT. However, the mechanisms responsible for monoaminergic damage are not specific for only neurons and likely cause damage to other cells in the brain. One class of cells that can be damaged by these mechanisms is those that which comprise the BBB.
Mechanisms of BBB Damage
The BBB can be disrupted by similar mechanisms that are responsible for Meth-induced monoaminergic damage and parallel those that are known to cause BBB disruption in a variety of other neurological diseases.
Extreme changes in body temperature are associated with increased BBB permeability. Kiyatkin and Sharma (2009) reported that both hyperthermia and hypothermia alter BBB function. Brains of rats, warmed to reach temperatures of 38.5–42°C, showed increases in albumin, GFAP-positive cells, water content and sodium, potassium and chloride concentrations, suggestive of brain edema. Moreover, the extent of BBB disruption was correlated with body temperature. Microwave-induced brain hyperthermia also results in horseradish peroxidase extravasation into the brain when brain temperatures were heated and maintained at 44.3°C for 30 min and 42.5°C for 60 min (Moriyama et al., 1991). Similarly, brain temperatures measured at hypothermic temperatures of 32–33°C also produced BBB leakage but to a lesser extent than hyperthermia (Kiyatkin and Sharma, 2009) and did not result in increases in brain water or ion content. These data suggest that alterations in brain temperatures alone can increase permeability of the BBB.
The role of oxidative stress in BBB disruption has been well-characterized. Oxidative stress is associated with BBB disruption in a variety of neurodegenerative disorders that have concomitant BBB disruption. Moreover, attenuation of oxidative damage is associated with protection against BBB damage (Kamada et al., 2007; Sharma et al., 2007; Ji et al., 2010, 2012; Price et al., 2012; Zehendner et al., 2013). Cerebrovascular endothelial cells in culture are damaged by 4-hydroxynonenal (HNE) (Karlhuber et al., 1997) and oxidized low-density lipoprotein (LDL), both of which are prevented by the antioxidant, resveratrol (Lin et al., 2010). Additionally, the free radical scavenger, edaravone, prevents oxidative stress, decreases in the BBB structural tight junction protein occludin, and increased BBB permeability to sodium-fluorescein produced by tissue plasminogen activator (tPA) in rats (Lukic-Panin et al., 2010). Furthermore, transgenic mice overexpressing copper/zinc superoxide dismutase are resistant to ischemia-induced free radical production and Evans blue leakage (Kim et al., 2001). In contrast, decreased copper/zinc superoxide dismutase activity enhances ischemia-induced edema in mice (Kondo et al., 1997). Together these findings illustrate a prominent role for oxidative stress in BBB damage after a variety of insults.
Mitochondrial dysfunction produces ROS and is also associated with BBB disruption in the context of Parkinson's Disease (PD) and Huntington's Disease (HD). Intrastriatal injection of the mitochondrial toxin 3-nitropropionic acid (3-NP), used as a model of HD, produced extravasation of Evans blue into the brain parenchyma as early as 3 h after administration of 3-NP while Evans blue extravasation and increased brain water content persisted for as long as 3 days after intrastriatal administration of 3-NP (Sato et al., 1997).
Excess extracellular glutamate can also lead to ROS and RNS production and possibly BBB disruption. Activation of ionotropic calcium permeable glutamate receptors, such as NMDA and AMPA receptors, results in an increase in intracellular calcium and subsequent activation of caspases and calpains as well as production of nitric oxide and reactive oxygen species (Siman and Noszek, 1988; Izumi et al., 1992). Consequently, increases in extracellular glutamate can be toxic to brain endothelial cells since they express NMDA receptors (Krizbai et al., 1998) and respond with increases in calcium influx and oxidative stress (Sharp et al., 2005; Neuhaus et al., 2011). In addition, exposure to glutamate decreases expression of the brain endothelial cell transmembrane protein, occludin (Andras et al., 2007; Neuhaus et al., 2011). Furthermore, increases in BBB permeability have been observed in response to seizure activity produced by a variety of convulsive agents (Nitsch and Klatzo, 1983; Pont et al., 1995) but it is unclear whether BBB disruption is a cause or consequence of seizure activity (for review, see Oby and Janigro, 2006). Thus, while excess extracellular glutamate likely contributes to BBB disruption, further studies are required to determine the role of glutamate in BBB disruption.
Lastly, inflammation is associated with BBB disruption. For example, the quintessential neuroinflammatory disease, Multiple Sclerosis (MS), presents with BBB disruption (Kermode et al., 1990). More specifically, TNFα expression and permeability of the BBB to endogenous albumin is produced by ischemia and treatment with an antibody against TNFα, attenuated ischemia-induced BBB damage (Yang et al., 1999). Pro-inflammatory mediators, such as cyclooxygenase (COX) also contribute to BBB disruption. COX inhibitors prevent ischemia- and TBI-induced BBB disruption (Mohanty et al., 1980; Ting, 1990; Candelario-Jalil et al., 2007; Hakan et al., 2010). Furthermore, prostaglandins are products of COX activity and mediate BBB disruption in a stroke model through EP1 receptor (EP1R) activation (Fukumoto et al., 2010). While it is unknown how EP1R activation increases BBB permeability, it may be through the signal transduction pathways that activate kinases (Bos et al., 2004) and subsequent phosphorylation of TJs. In fact, Rho kinase (ROCK) activity is stimulated by the EP1R (Wolkowicz et al., 2002), phosphorylates occludin and claudin-5 in brain endothelial cells (Yamamoto et al., 2008) and results in the loss of integrity of TJs in HIV-encephalitis models (Persidsky et al., 2006). Overall, there is significant support for the role of inflammation in BBB disruption.
Meth-Induced BBB Damage
More recently, the BBB has been identified as a target of Meth and a change in the BBB is thought to be a consequence of the acute effects of Meth, similar to Meth-induced monoamine terminal damage. The majority of evidence is provided by preclinical studies that illustrate the effects of Meth on BBB structural proteins, the tight junction proteins, as well as BBB function.
Bowyer and Ali (2006) were the first to identify an increase in BBB permeability to endogenous IgG, as early as 90 min after exposure of rats to a single high dose of Meth, but this effect seemed to recover by 3 days after Meth exposure. Increases in IgG were apparent in the hippocampus and amygdala but only in rats that became hyperthermic and had seizures. Lower doses of Meth also increase permeability to Evans blue and FITC-labeled albumin within 24 h of Meth exposure (Kiyatkin et al., 2007; Kousik et al., 2011). These early increases in BBB permeability may be due to hyperthermia since the extent of increases in Evans blue and water content in the brain directly correlate with brain temperature (Kiyatkin et al., 2007). Transient changes in BBB structures have also been noted after Meth exposure. A single high dose of Meth to mice decreased expression of BBB structural tight junction proteins including occludin, claudin-5, and ZO, 24 h after Meth exposure (Martins et al., 2011). The mechanism underlying these changes may be associated with an increase in activated matrix metalloprotease-9 (MMP-9), which also has been demonstrated to play a major role in inflammation and ischemia-reperfusion-induced disruption of tight junction proteins and increase in BBB permeability (Mun-Bryce and Rosenberg, 1998; Yang et al., 2007). It remains to be determined whether MMP-9 plays a causative role in Meth-induced BBB disruption, however, hyperthermia contributes to the acute BBB disruption observed after a single high dose of Meth.
The contribution of oxidative stress in Meth-induced BBB disruption has also been studied. Exposure of cultured brain microvascular endothelial cells to Meth exhibit decreased expression of occludin, claudin-5 and zona occludens (ZO) as well as decreased transendothelial electrical resistance (TEER), indicative of increased paracellular permeability (Mahajan et al., 2008; Ramirez et al., 2009). These alterations in endothelial structures and function are associated with increases in ROS such that the antioxidant, Trolox, reduced Meth-induced decreases in TEER in endothelial cells in culture as well as extravasation of sodium-fluorescein in mice, observed 2 days after exposure to Meth (Ramirez et al., 2009).
Cells other than brain microvascular endothelial cells are responsible for BBB integrity. Astrocytes extend their endfeet to contact endothelial cells and help to stabilize and maintain BBB function (for review, see Abbott, 2000). One protein on astrocytes, β-dystroglycan, crosslinks astrocytic endfeet to endothelial cells and helps maintain a hydrophobic barrier and regulates aquaporin 4 (AQP4) localization. Thus, decreased expression of β-dystroglycan expression or truncation of its full form may prevent the localization of AQP4 to astrocytic endfeet and compromise the ability of AQP4 to regulate water clearance in the brain parenchyma (Papadopoulos et al., 2004). In fact, binge Meth exposure results in increased truncation of β-dystroglycan and increases in brain water content at 24 h (Northrop and Yamamoto, 2012). In addition, Meth acutely damages epithelial cells of the choroid plexus (Sharma and Kiyatkin, 2009), a structure involved in regulating water exchange between the brain and blood, which could also contribute to Meth-induced brain edema.
Another cell type that interacts with endothelial cells and helps to maintain proper BBB function are pericytes. Pericytes maintain proper BBB function including induction of tight junction and basement membrane formation, support of astrocytes in end-foot distribution and polarization and regulation of blood flow. Thus, an impairment of pericytes could dysregulate BBB function (for review, see Winkler et al., 2011). Pericytes can be damaged via mechanisms similar to those responsible for Meth-induced disruption of brain endothelial cells. For example, oxidative damage to pericytes in response to hyperglycemia and mitochondrial stress cause cell damage that can be prevented by antioxidant treatment (Price et al., 2012; May et al., 2014; Okada et al., 2014). Since pericytes express functional NMDA glutamate receptors (Montiel-Eulefi et al., 2012), they can be activated by Meth-induced glutamate release and in turn, lead to excitotoxicity. In addition, activation of glutamate receptors produces RNS and s-nitrosylation activates MMP-2 and MMP-9, two proteases known to disrupt tight junction proteins (Gu et al., 2002). Furthermore, inflammation may mediate the effects of Meth on pericytes as LPS infection can dissociate pericytes from endothelial cells and the basement membrane and increase BBB permeability (Nishioku et al., 2009).
Meth-induced peripheral organ damage, such as liver, muscle and kidney, can also lead to BBB disruption. Peripheral organ damage can lead to increases in circulating and brain ammonia concentrations through increases in brain glutamate (Chan et al., 2000; Gorg et al., 2010; Halpin et al., 2014). Ammonia can also induce oxidative stress via superoxide and nitric oxide production as well as through decreases in antioxidant enzymes (Kosenko et al., 1997a,b). Consequently, ammonia may result in oxidative damage of endothelial cells or activation of MMPs. In addition, excess ammonia can result in neuroinflammation marked by increases in microglial and astrocytic activation, pro-inflammatory cytokines and prostaglandin E2 (PGE2) (Rodrigo et al., 2010; Bemeur and Butterworth, 2012). Thus, ammonia may also be a contributing factor to Meth-induced BBB damage via oxidative, excitotoxic and/or inflammatory dependent manners.
It is important to note that Meth use, similar to other drugs of abuse, does not occur in isolation. Comorbidities associated with Meth, including stress disorders, use of other drugs and HIV infection, may potentiate the effects of Meth on the BBB.
Stress is highly comorbid with drug use. Stressors increase ROS (Mcintosh and Sapolsky, 1996; Leza et al., 1998; Madrigal et al., 2001), inflammatory mediators (Minami et al., 1991; Garcia-Bueno et al., 2008), mitochondrial dysfunction (Madrigal et al., 2001) and extracellular glutamate (Moghaddam, 1993). As mentioned previously, these mechanisms contribute to Meth-induced BBB disruption in response to a variety of insults. Thus, it is likely that stress could exacerbate Meth-induced BBB disruption by potentiating Meth-induced increases in ROS, inflammatory mediators, mitochondrial dysfunction, and extracellular glutamate.
In fact, serial exposure to 10 days of chronic unpredictable stress (CUS) and Meth produce an enhanced damage of the BBB, compared to stress or Meth alone at 24 h after Meth exposure. This damage was evidenced by decreases in the tight junction proteins, occludin and claudin-5, truncation of the astrocytic endfeet protein β-dystroglycan, as well as increases in BBB permeability to water and 10,000 Da FITC-dextran (Northrop and Yamamoto, 2012). Furthermore, the combination of stress and Meth but not Meth alone, prolonged BBB disruption in a manner that was paralleled by an increase in inflammatory markers, GFAP and COX-2, up to 7 days after exposure to stress and Meth (Northrop and Yamamoto, 2012). In addition, the non-selective COX inhibitor, ketoprofen, prevented the disruption in BBB structure and function observed at 7 days, when ketoprofen was administered after, but not during exposure to stress and Meth (Northrop and Yamamoto, 2012). This illustrates that the combination of stress and Meth produces a delayed increase in neuroinflammation that is responsible for the prolonged breach in the BBB. Therefore, these findings illustrate that stress enhances Meth-induced early BBB disruption and prolongs the opening of the BBB, as compared to Meth alone in a manner that is dependent on COX activity. Other mechanisms by which stress can enhance Meth-induced BBB damage, such as oxidative stress, mitochondrial dysfunction and glutamate remain to be examined.
Ethanol is one drug that is frequently abused in combination with Meth. Ethanol can directly damage brain microvascular endothelial cells (BMVECs) in culture. Exposure to ethanol produces activation of myosin light chain kinase and consequent phosphorylation and degradation of tight junction proteins, occludin, claudin-5 and ZO-1. Furthermore, a decrease in barrier function evidenced by a decrease in TEER and an increase in monocyte migration are observed in BMVECs exposed to ethanol. Moreover, the effects of ethanol on tight junction proteins and barrier function were associated with increases in ROS, resulting from ethanol metabolism, and increased calcium concentrations and were prevented by antioxidant treatment or an inhibitor of the intracellular calcium modulator, inositol 1,4,5-triphosphate receptor (IP3R) (Haorah et al., 2005, 2007). The effects of ethanol on the BBB in rodents however are less clear. Chronic treatment of rats with 20% ethanol in drinking water for 12 months produces BBB disruption as evidenced by increased BBB permeability to endogenous IgG in the cortex (Ehrlich and Humpel, 2012). Similarly, 2 weeks of a 5% liquid alcohol diet increased BBB permeability to radioactively labeled leptin (Pan et al., 2008). In contrast, 7.5% ethanol in drinking water for 6 months had no effect on permeability of the BBB to sucrose (Phillips, 1981) nor did acute ethanol intoxication affect BBB permeability (Hemmingsen et al., 1980; Pan et al., 2008). Moreover, some studies suggest that acute ethanol may even protect against BBB disruption resulting in stroke models (Zeng et al., 2012; Peng et al., 2013), but others suggest a detrimental effect of ethanol in HIV Tat and gp120-induced endothelial cell death and BBB permeability (Acheampong et al., 2002; Shiu et al., 2007). Thus, ethanol alone can have protective or detrimental effects on BBB function depending on dose and length of exposure. In combination with Meth, however, ethanol could potentiate Meth-induced BBB disruption through its pro-inflammatory (Le Moine et al., 1995; Mathurin et al., 2000) and pro-oxidant (Haorah et al., 2007) effects.
Meth use is also highly comorbid with HIV infection and the combination of HIV infection and Meth can enhance BBB disruption. The BBB is affected by HIV infection and is also involved in the progression of disease (for review, see Banks et al., 2006). While HIV-induced increases in BBB permeability may not be the sole reason for immune cells and virus infiltration into the brain, HIV proteins act on BMECs and result in increased neuroinflammation. Therefore, HIV infection could exacerbate Meth-induced BBB damage.
The HIV proteins, Tat and gp120, alone or in combination, cause BBB disruption via oxidative and inflammatory mechanisms (Toborek et al., 2003; Price et al., 2005). Decreases in tight junction proteins, claudin-1, claudin-5, and ZO-2 in BMVECs as well as cytotoxicity of BMVECs were observed after treatment with HIV Tat (Andras et al., 2003; Khan et al., 2003; Kim et al., 2003). Furthermore, acute administration of gp-120 or cellular expression of gp-120 caused the extravasation of Evans blue into the brain and decreased the tight junction protein, claudin-5. These alterations in BBB were associated with increased expression of MMP-2 and MMP-9. Moreover, when MMP expression was inhibited via antioxidants or an NMDA receptor antagonist, the gp-120-induced BBB disruption was prevented (Louboutin et al., 2010). Therefore, HIV infection may exacerbate Meth-induced BBB disruption via oxidative, inflammatory or glutamate dependent mechanisms.
In fact, administration of the HIV proteins Tat and gp120 in combination with Meth to mice decreased tight junction protein expression and increased BBB permeability to sodium-fluorescein. These changes were associated with decreases in glutathione and increased oxidation of lipids and proteins that were attenuated by treatment with the antioxidant, N-acetylcysteine amide (NACA) (Banerjee et al., 2010). This further supports the interaction of HIV infection and Meth at the BBB as well as role for oxidative stress in HIV and Meth-induced BBB disruption. However, more investigation is necessary for a clear understanding of the interaction of HIV infection and Meth in humans as well as the role of inflammation and glutamate in HIV and Meth-induced BBB disruption.
Consequences of Meth-Induced BBB Disruption
The opening of the BBB can have broad and significant consequences, particularly with regard to Meth use. These consequences may manifest as enhanced vulnerability to other disease states that are co-morbid with Meth use such as stress, HIV infection (Swan, 1997) and Hepatitis C. In fact, Meth users have higher Hepatitis C and HIV viral titers in their brain as compared with non-Meth users (Letendre et al., 2005, 2007; Nath, 2010).
Meth abuse is also associated with other infections. Meth abuse produces what has been informally termed “Meth mouth.” “Meth mouth” is characterized by extensive tooth decay, bruxism, and dry mouth (Rhodus and Little, 2008), all of which can lead to bacterial infections and periodontal gum disease. A primary culprit of periodontal disease is Porphyromonas gingivalis (P. gingivalis), a bacterium also linked to rheumatoid arthritis and atherosclerosis (Iwai, 2009; Berthelot and Le Goff, 2010). Few studies have examined its appearance and action in the brain, although there is evidence that P. gingivalis can activate microglial cells in culture (Shapira et al., 2002). Therefore, the brains of Meth users could be extremely vulnerable to infection by HIV, Hepatitis C and P. gingivalis, which can lead to enhanced inflammatory responses and further brain damage.
More generally, Meth-induced BBB disruption may be the cause of the cognitive decline and depression seen in Meth users. BBB disruption is a pathological symptom of Alzheimer's disease and BBB disruption is thought to play a role in cognitive decline and dementia (for review, see Van De Haar et al., 2014); however, the exact mechanisms are unknown. BBB disruption also leads to increases in infiltration of immune cells and inflammatory mediators, which could affect normal brain physiology and function. For example, neuroinflammation is thought to precipitate depression (for review, see Najjar et al., 2013) and may underlie the depression associated with long-term use of Meth.
In contrast to the negative consequences of BBB disruption, an opening of the BBB may facilitate the entry of therapeutics that normally cannot enter the brain such as those used to treat some neurodegenerative disorders or brain cancers. Thus, basic knowledge about how Meth opens the BBB and the mechanisms that underlie its acute and long-term effects may provide clues as to how transient and persistent changes in the BBB can be differentiated by other means than Meth exposure to facilitate acute entry of therapeutic drugs into the brain.
Meth results in disruption of BBB structure and function and the mechanisms that contribute to BBB disruption are similar to those that are responsible for monoaminergic terminal damage after Meth. However, more studies are needed to assign a causative role for inflammation, glutamate and ammonia in Meth-induced BBB disruption. Furthermore, comorbidities of Meth including stress, poly-drug use and HIV infection could exacerbate the damaging effects of Meth on the BBB. These findings and possibilities highlight the urgency for new research to identify the precise mechanisms that lead to the development of therapeutics to treat the far-reaching and significant consequences of Meth-induced BBB disruption.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors gratefully acknowledge support from National Institute of Health, DA007606 and DA035499.
Abekawa, T., Ohmori, T., and Koyama, T. (1996). Effects of nitric oxide synthesis inhibition on methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain. J. Neural. Transm. 103, 671–680. doi: 10.1007/BF01271227
Acheampong, E., Mukhtar, M., Parveen, Z., Ngoubilly, N., Ahmad, N., Patel, C., et al. (2002). Ethanol strongly potentiates apoptosis induced by HIV-1 proteins in primary human brain microvascular endothelial cells. Virology 304, 222–234. doi: 10.1006/viro.2002.1666
Albers, D. S., and Sonsalla, P. K. (1995). Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275, 1104–1114.
Alper, G., Girgin, F. K., Ozgonul, M., Mentes, G., and Ersoz, B. (1999). MAO inhibitors and oxidant stress in aging brain tissue. Eur. Neuropsychopharmacol. 9, 247–252. doi: 10.1016/S0924-977X(98)00035-2
Andras, I. E., Deli, M. A., Veszelka, S., Hayashi, K., Hennig, B., and Toborek, M. (2007). The NMDA and AMPA/KA receptors are involved in glutamate-induced alterations of occludin expression and phosphorylation in brain endothelial cells. J. Cereb. Blood Flow Metab. 27, 1431–1443. doi: 10.1038/sj.jcbfm.9600445
Andras, I. E., Pu, H., Deli, M. A., Nath, A., Hennig, B., and Toborek, M. (2003). HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J. Neurosci. Res. 74, 255–265. doi: 10.1002/jnr.10762
Banerjee, A., Zhang, X., Manda, K. R., Banks, W. A., and Ercal, N. (2010). HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic. Biol. Med. 48, 1388–1398. doi: 10.1016/j.freeradbiomed.2010.02.023
Battaglia, G., Fornai, F., Busceti, C. L., Aloisi, G., Cerrito, F., De Blasi, A., et al. (2002). Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22, 2135–2141.
Bemeur, C., and Butterworth, R. F. (2012). Liver-brain proinflammatory signalling in acute liver failure: role in the pathogenesis of hepatic encephalopathy and brain edema. Metab. Brain Dis. 2, 145–150. doi: 10.1007/s11011-012-9361-3
Bos, C. L., Richel, D. J., Ritsema, T., Peppelenbosch, M. P., and Versteeg, H. H. (2004). Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36, 1187–1205. doi: 10.1016/j.biocel.2003.08.006
Bowyer, J. F., and Ali, S. (2006). High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60, 521–532. doi: 10.1002/syn.20324
Bowyer, J. F., Davies, D. L., Schmued, L., Broening, H. W., Newport, G. D., Slikker, W. Jr., et al. (1994). Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268, 1571–1580.
Bowyer, J. F., Tank, A. W., Newport, G. D., Slikker, W. Jr., Ali, S. F., and Holson, R. R. (1992). The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmacol. Exp. Ther. 260, 817–824.
Brown, J. M., Quinton, M. S., and Yamamoto, B. K. (2005). Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite. J. Neurochem. 95, 429–436. doi: 10.1111/j.1471-4159.2005.03379.x
Cadet, J. L., Ali, S., and Epstein, C. (1994a). Involvement of oxygen-based radicals in methamphetamine-induced neurotoxicity: evidence from the use of CuZnSOD transgenic mice. Ann. N.Y. Acad. Sci. 738, 388–391. doi: 10.1111/j.1749-6632.1994.tb21827.x
Cadet, J. L., Sheng, P., Ali, S., Rothman, R., Carlson, E., and Epstein, C. (1994b). Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62, 380–383. doi: 10.1046/j.1471-4159.1994.62010380.x
Callahan, B. T., Cord, B. J., Yuan, J., McCann, U. D., and Ricaurte, G. A. (2001). Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity. J. Neurochem. 77, 1348–1362. doi: 10.1046/j.1471-4159.2001.00341.x
Candelario-Jalil, E., Taheri, S., Yang, Y., Sood, R., Grossetete, M., Estrada, E. Y., et al. (2007). Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J. Pharmacol. Exp. Ther. 323, 488–498. doi: 10.1124/jpet.107.127035
Chan, H., Hazell, A. S., Desjardins, P., and Butterworth, R. F. (2000). Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes. Neurochem. Int. 37, 243–248. doi: 10.1016/S0197-0186(00)00026-7
Chan, P., Di Monte, D. A., Luo, J. J., Delanney, L. E., Irwin, I., and Langston, J. W. (1994). Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62, 2484–2487. doi: 10.1046/j.1471-4159.1994.62062484.x
Chang, L., Ernst, T., Speck, O., and Grob, C. S. (2005). Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am. J. Psychiatry 162, 361–369. doi: 10.1176/appi.ajp.162.2.361
Chang, L., Ernst, T., Speck, O., Patel, H., Desilva, M., Leonido-Yee, M., et al. (2002). Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 114, 65–79. doi: 10.1016/S0925-4927(02)00004-5
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H. (1991). Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. U.S.A. 88, 6368–6371. doi: 10.1073/pnas.88.14.6368
Deng, X., Wang, Y., Chou, J., and Cadet, J. L. (2001). Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method. Brain Res. Mol. Brain Res. 93, 64–69. doi: 10.1016/S0169-328X(01)00184-X
Ehrlich, D., and Humpel, C. (2012). Chronic vascular risk factors (cholesterol, homocysteine, ethanol) impair spatial memory, decline cholinergic neurons and induce blood-brain barrier leakage in rats in vivo. J. Neurol. Sci. 322, 92–95. doi: 10.1016/j.jns.2012.07.002
Ernst, T., Chang, L., Leonido-Yee, M., and Speck, O. (2000). Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54, 1344–1349. doi: 10.1212/WNL.54.6.1344
Escubedo, E., Guitart, L., Sureda, F. X., Jimenez, A., Pubill, D., Pallas, M., et al. (1998). Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814, 120–126. doi: 10.1016/S0006-8993(98)01065-8
Eyerman, D. J., and Yamamoto, B. K. (2007). A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J. Neurochem. 103, 1219–1227. doi: 10.1111/j.1471-4159.2007.04837.x
Flora, G., Lee, Y. W., Nath, A., Maragos, W., Hennig, B., and Toborek, M. (2002). Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med. 2, 71–85. doi: 10.1385/NMM:2:1:71
Fukami, G., Hashimoto, K., Koike, K., Okamura, N., Shimizu, E., and Iyo, M. (2004). Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 1016, 90–95. doi: 10.1016/j.brainres.2004.04.072
Fukumoto, K., Takagi, N., Yamamoto, R., Moriyama, Y., Takeo, S., and Tanonaka, K. (2010). Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur. J. Pharmacol. 640, 82–86. doi: 10.1016/j.ejphar.2010.05.001
Garcia-Bueno, B., Madrigal, J. L., Perez-Nievas, B. G., and Leza, J. C. (2008). Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats. Endocrinology 149, 1969–1978. doi: 10.1210/en.2007-0482
Goncalves, J., Baptista, S., Martins, T., Milhazes, N., Borges, F., Ribeiro, C. F., et al. (2010). Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur. J. Neurosci. 31, 315–326. doi: 10.1111/j.1460-9568.2009.07059.x
Goncalves, J., Martins, T., Ferreira, R., Milhazes, N., Borges, F., Ribeiro, C. F., et al. (2008). Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann. N.Y. Acad. Sci. 1139, 103–111. doi: 10.1196/annals.1432.043
Gorg, B., Morwinsky, A., Keitel, V., Qvartskhava, N., Schror, K., and Haussinger, D. (2010). Ammonia triggers exocytotic release of L-glutamate from cultured rat astrocytes. Glia 58, 691–705. doi: 10.1002/glia.20955
Graham, D. G., Tiffany, S. M., Bell, W. R. Jr., and Gutknecht, W. F. (1978). Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644–653.
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., et al. (2002). S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186–1190. doi: 10.1126/science.1073634
Hakan, T., Toklu, H. Z., Biber, N., Ozevren, H., Solakoglu, S., Demirturk, P., et al. (2010). Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol. Res. 32, 629–635. doi: 10.1179/016164109X12464612122731
Halpin, L. E., Northrop, N. A., and Yamamoto, B. K. (2014). Ammonia mediates methamphetamine-induced increases in glutamate and excitotoxicity. Neuropsychopharmacology 39, 1031–1038. doi: 10.1038/npp.2013.306
Haorah, J., Heilman, D., Knipe, B., Chrastil, J., Leibhart, J., Ghorpade, A., et al. (2005). Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcohol. Clin. Exp. Res. 29, 999–1009. doi: 10.1097/01.ALC.0000166944.79914.0A
Haorah, J., Knipe, B., Gorantla, S., Zheng, J., and Persidsky, Y. (2007). Alcohol-induced blood-brain barrier dysfunction is mediated via inositol 1,4,5-triphosphate receptor (IP3R)-gated intracellular calcium release. J. Neurochem. 100, 324–336. doi: 10.1111/j.1471-4159.2006.04245.x
Hastings, T. G., Lewis, D. A., and Zigmond, M. J. (1996). Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv. Exp. Med. Biol. 387, 97–106. doi: 10.1007/978-1-4757-9480-9_13
Hemmingsen, R., Hertz, M. M., and Bolwig, T. G. (1980). Integrity of blood-brain barrier during ethanol intoxication and withdrawal in the rat: normal glucose transfer and permeability to Na+ and Cl. Stroke 11, 141–144. doi: 10.1161/01.STR.11.2.141
Hirata, H., Ladenheim, B., Rothman, R. B., Epstein, C., and Cadet, J. L. (1995). Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res. 677, 345–347. doi: 10.1016/0006-8993(95)00218-F
Hotchkiss, A. J., and Gibb, J. W. (1980). Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214, 257–262.
Imam, S. Z., El-Yazal, J., Newport, G. D., Itzhak, Y., Cadet, J. L., Slikker, W. Jr., et al. (2001a). Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. N.Y. Acad. Sci. 939, 366–380. doi: 10.1111/j.1749-6632.2001.tb03646.x
Imam, S. Z., Newport, G. D., Itzhak, Y., Cadet, J. L., Islam, F., Slikker, W. Jr., et al. (2001b). Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76, 745–749. doi: 10.1046/j.1471-4159.2001.00029.x
Itzhak, Y., Gandia, C., Huang, P. L., and Ali, S. F. (1998). Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J. Pharmacol. Exp. Ther. 284, 1040–1047.
Itzhak, Y., Martin, J. L., and Ail, S. F. (2000). nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 11, 2943–2946. doi: 10.1097/00001756-200009110-00022
Ji, H., Zhang, X., Du, Y., Liu, H., Li, S., and Li, L. (2012). Polydatin modulates inflammation by decreasing NF-kappaB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res. Bull. 87, 50–59. doi: 10.1016/j.brainresbull.2011.09.021
Ji, X., Liu, W., Xie, K., Qu, Y., Chao, X., Chen, T., et al. (2010). Beneficial effects of hydrogen gas in a rat model of traumatic brain injury via reducing oxidative stress. Brain Res. 1354, 196–205. doi: 10.1016/j.brainres.2010.07.038
Kamada, H., Yu, F., Nito, C., and Chan, P. H. (2007). Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke 38, 1044–1049. doi: 10.1161/01.STR.0000258041.75739.cb
Kermode, A. G., Thompson, A. J., Tofts, P., Macmanus, D. G., Kendall, B. E., Kingsley, D. P., et al. (1990). Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113 (Pt 5), 1477–1489. doi: 10.1093/brain/113.5.1477
Khan, N. A., Di Cello, F., Nath, A., and Kim, K. S. (2003). Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells. J. Neurovirol. 9, 584–593. doi: 10.1080/jnv.9.6.584.593
Kim, G. W., Lewen, A., Copin, J., Watson, B. D., and Chan, P. H. (2001). The cytosolic antioxidant, copper/zinc superoxide dismutase, attenuates blood-brain barrier disruption and oxidative cellular injury after photothrombotic cortical ischemia in mice. Neuroscience 105, 1007–1018. doi: 10.1016/S0306-4522(01)00237-8
Kim, T. A., Avraham, H. K., Koh, Y. H., Jiang, S., Park, I. W., and Avraham, S. (2003). HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J. Immunol. 170, 2629–2637. doi: 10.4049/jimmunol.170.5.2629
Kish, S. J., Fitzmaurice, P. S., Boileau, I., Schmunk, G. A., Ang, L. C., Furukawa, Y., et al. (2009). Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) 202, 649–661. doi: 10.1007/s00213-008-1346-x
Kitamura, O., Tokunaga, I., Gotohda, T., and Kubo, S. (2007). Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int. J. Legal Med. 121, 163–168. doi: 10.1007/s00414-006-0087-9
Kiyatkin, E. A., Brown, P. L., and Sharma, H. S. (2007). Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur. J. Neurosci. 26, 1242–1253. doi: 10.1111/j.1460-9568.2007.05741.x
Kondo, T., Reaume, A. G., Huang, T. T., Carlson, E., Murakami, K., Chen, S. F., et al. (1997). Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J. Neurosci. 17, 4180–4189.
Kosenko, E., Felipo, V., Montoliu, C., Grisolia, S., and Kaminsky, Y. (1997a). Effects of acute hyperammonemia in vivo on oxidative metabolism in nonsynaptic rat brain mitochondria. Metab. Brain Dis. 12, 69–82. doi: 10.1007/BF02676355
Kosenko, E., Kaminsky, Y., Kaminsky, A., Valencia, M., Lee, L., Hermenegildo, C., et al. (1997b). Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic. Res. 27, 637–644. doi: 10.3109/10715769709097867
Kousik, S. M., Graves, S. M., Napier, T. C., Zhao, C., and Carvey, P. M. (2011). Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction. Neuroreport 22, 923–928. doi: 10.1097/WNR.0b013e32834d0bc8
Krizbai, I. A., Deli, M. A., Pestenacz, A., Siklos, L., Szabo, C. A., Andras, I., et al. (1998). Expression of glutamate receptors on cultured cerebral endothelial cells. J. Neurosci. Res. 54, 814–819.
Ladenheim, B., Krasnova, I. N., Deng, X., Oyler, J. M., Polettini, A., Moran, T. H., et al. (2000). Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol. Pharmacol. 58, 1247–1256. doi: 10.1124/mol.58.6.1247
Lavoie, M. J., Card, J. P., and Hastings, T. G. (2004). Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 187, 47–57. doi: 10.1016/j.expneurol.2004.01.010
Lavoie, M. J., and Hastings, T. G. (1999). Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 73, 2546–2554. doi: 10.1046/j.1471-4159.1999.0732546.x
Le Moine, O., Marchant, A., De Groote, D., Azar, C., Goldman, M., and Deviere, J. (1995). Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 22, 1436–1439. doi: 10.1002/hep.1840220516
Letendre, S. L., Cherner, M., Ellis, R. J., Marquie-Beck, J., Gragg, B., Marcotte, T., et al. (2005). The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (19 Suppl. 3), S72–S78. doi: 10.1097/01.aids.0000192073.18691.ff
Letendre, S., Paulino, A. D., Rockenstein, E., Adame, A., Crews, L., Cherner, M., et al. (2007). Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J. Infect. Dis. 196, 361–370. doi: 10.1086/519285
Leza, J. C., Salas, E., Sawicki, G., Russell, J. C., and Radomski, M. W. (1998). The effects of stress on homeostasis in JCR-LA-cp rats: the role of nitric oxide. J. Pharmacol. Exp. Ther. 286, 1397–1403.
Lin, Y. L., Chang, H. C., Chen, T. L., Chang, J. H., Chiu, W. T., Lin, J. W., et al. (2010). Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J. Nutr. 140, 2187–2192. doi: 10.3945/jn.110.123505
Loftis, J. M., Choi, D., Hoffman, W., and Huckans, M. S. (2011). Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox. Res. 20, 59–68. doi: 10.1007/s12640-010-9223-x
Louboutin, J. P., Agrawal, L., Reyes, B. A., Van Bockstaele, E. J., and Strayer, D. S. (2010). HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J. Neuropathol. Exp. Neurol. 69, 801–816. doi: 10.1097/NEN.0b013e3181e8c96f
Lukic-Panin, V., Deguchi, K., Yamashita, T., Shang, J., Zhang, X., Tian, F., et al. (2010). Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr. Neurovasc. Res. 7, 319–329. doi: 10.2174/156720210793180747
Madrigal, J. L., Olivenza, R., Moro, M. A., Lizasoain, I., Lorenzo, P., Rodrigo, J., et al. (2001). Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 24, 420–429. doi: 10.1016/S0893-133X(00)00208-6
Mahajan, S. D., Aalinkeel, R., Sykes, D. E., Reynolds, J. L., Bindukumar, B., Adal, A., et al. (2008). Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 1203, 133–148. doi: 10.1016/j.brainres.2008.01.093
Maragos, W. F., Jakel, R., Chesnut, D., Pocernich, C. B., Butterfield, D. A., St Clair, D., et al. (2000). Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase. Brain Res. 878, 218–222. doi: 10.1016/S0006-8993(00)02707-4
Mark, K. A., Soghomonian, J. J., and Yamamoto, B. K. (2004). High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 24, 11449–11456. doi: 10.1523/JNEUROSCI.3597-04.2004
Martins, T., Baptista, S., Goncalves, J., Leal, E., Milhazes, N., Borges, F., et al. (2011). Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 1411, 28–40. doi: 10.1016/j.brainres.2011.07.013
Mathurin, P., Deng, Q. G., Keshavarzian, A., Choudhary, S., Holmes, E. W., and Tsukamoto, H. (2000). Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 32, 1008–1017. doi: 10.1053/jhep.2000.19621
May, J. M., Jayagopal, A., Qu, Z. C., and Parker, W. H. (2014). Ascorbic acid prevents high glucose-induced apoptosis in human brain pericytes. Biochem. Biophys. Res. Commun. 452, 112–117. doi: 10.1016/j.bbrc.2014.08.057
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., and Ricaurte, G. A. (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 18, 8417–8422.
Mcintosh, L. J., and Sapolsky, R. M. (1996). Glucocorticoids increase the accumulation of reactive oxygen species and enhance adriamycin-induced toxicity in neuronal culture. Exp. Neurol. 141, 201–206. doi: 10.1006/exnr.1996.0154
Minami, M., Kuraishi, Y., Yamaguchi, T., Nakai, S., Hirai, Y., and Satoh, M. (1991). Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. Neurosci. Lett. 123, 254–256. doi: 10.1016/0304-3940(91)90944-O
Moghaddam, B. (1993). Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J. Neurochem. 60, 1650–1657. doi: 10.1111/j.1471-4159.1993.tb13387.x
Mohanty, S., Ray, A. K., and Dey, P. K. (1980). Cerebral oedema and blood-brain and blood-CSF barriers in experimental brain trauma: effect of indomethacin-A prostaglandin synthetase inhibitor. Indian J. Physiol. Pharmacol. 24, 91–96.
Moriyama, E., Salcman, M., and Broadwell, R. D. (1991). Blood-brain barrier alteration after microwave-induced hyperthermia is purely a thermal effect: I. Temperature and power measurements. Surg. Neurol. 35, 177–182. doi: 10.1016/0090-3019(91)90068-K
Moszczynska, A., Fitzmaurice, P., Ang, L., Kalasinsky, K. S., Schmunk, G. A., Peretti, F. J., et al. (2004). Why is parkinsonism not a feature of human methamphetamine users? Brain 127, 363–370. doi: 10.1093/brain/awh046
Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., et al. (2004). Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J. Neurosci. 24, 2212–2225. doi: 10.1523/JNEUROSCI.4847-03.2004
Nath, A. (2010). Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann. N.Y. Acad. Sci. 1187, 122–128. doi: 10.1111/j.1749-6632.2009.05277.x
Neuhaus, W., Freidl, M., Szkokan, P., Berger, M., Wirth, M., Winkler, J., et al. (2011). Effects of NMDA receptor modulators on a blood-brain barrier in vitro model. Brain Res. 1394, 49–61. doi: 10.1016/j.brainres.2011.04.003
Nishioku, T., Dohgu, S., Takata, F., Eto, T., Ishikawa, N., Kodama, K. B., et al. (2009). Detachment of brain pericytes from the basal lamina is involved in disruption of the blood-brain barrier caused by lipopolysaccharide-induced sepsis in mice. Cell. Mol. Neurobiol. 29, 309–316. doi: 10.1007/s10571-008-9322-x
Nitsch, C., and Klatzo, I. (1983). Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J. Neurol. Sci. 59, 305–322. doi: 10.1016/0022-510X(83)90016-3
Northrop, N. A., and Yamamoto, B. K. (2012). Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood-brain barrier. J. Neuroimmune Pharmacol. 7, 951–968. doi: 10.1007/s11481-012-9391-y
Okada, R., Wu, Z., Zhu, A., Ni, J., Zhang, J., Yoshimine, Y., et al. (2014). Cathepsin D deficiency induces oxidative damage in brain pericytes and impairs the blood-brain barrier. Mol. Cell. Neurosci. 64C, 51–60. doi: 10.1016/j.mcn.2014.12.002
Pan, W., Barron, M., Hsuchou, H., Tu, H., and Kastin, A. J. (2008). Increased leptin permeation across the blood-brain barrier after chronic alcohol ingestion. Neuropsychopharmacology 33, 859–866. doi: 10.1038/sj.npp.1301452
Papadopoulos, M. C., Manley, G. T., Krishna, S., and Verkman, A. S. (2004). Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 18, 1291–1293. doi: 10.1096/fj.04-1723fje
Peng, C., Li, W. A., Fu, P., Chakraborty, T., Hussain, M., Guthikonda, M., et al. (2013). At low doses ethanol maintains blood-brain barrier (BBB) integrity after hypoxia and reoxygenation: a brain slice study. Neurol. Res. 35, 790–797. doi: 10.1179/1743132813Y.0000000198
Persidsky, Y., Heilman, D., Haorah, J., Zelivyanskaya, M., Persidsky, R., Weber, G. A., et al. (2006). Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107, 4770–4780. doi: 10.1182/blood-2005-11-4721
Pont, F., Collet, A., and Lallement, G. (1995). Early and transient increase of rat hippocampal blood-brain barrier permeability to amino acids during kainic acid-induced seizures. Neurosci. Lett. 184, 52–54. doi: 10.1016/0304-3940(94)11166-G
Price, T. O., Eranki, V., Banks, W. A., Ercal, N., and Shah, G. N. (2012). Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 153, 362–372. doi: 10.1210/en.2011-1638
Price, T. O., Ercal, N., Nakaoke, R., and Banks, W. A. (2005). HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res. 1045, 57–63. doi: 10.1016/j.brainres.2005.03.031
Raiteri, M., Cerrito, F., Cervoni, A. M., and Levi, G. (1979). Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208, 195–202.
Ramirez, S. H., Potula, R., Fan, S., Eidem, T., Papugani, A., Reichenbach, N., et al. (2009). Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J. Cereb. Blood Flow Metab. 29, 1933–1945. doi: 10.1038/jcbfm.2009.112
Ricaurte, G. A., Schuster, C. R., and Seiden, L. S. (1980). Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193, 153–163. doi: 10.1016/0006-8993(80)90952-X
Rodrigo, R., Cauli, O., Gomez-Pinedo, U., Agusti, A., Hernandez-Rabaza, V., Garcia-Verdugo, J. M., et al. (2010). Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 139, 675–684. doi: 10.1053/j.gastro.2010.03.040
Sanchez, V., Zeini, M., Camarero, J., O'shea, E., Bosca, L., Green, A. R., et al. (2003). The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. J. Neurochem. 85, 515–524. doi: 10.1046/j.1471-4159.2003.01714.x
Sato, S., Gobbel, G. T., Li, Y., Kondo, T., Murakami, K., Sato, M., et al. (1997). Blood-brain barrier disruption, HSP70 expression and apoptosis due to 3-nitropropionic acid, a mitochondrial toxin. Acta Neurochir. Suppl. 70, 237–239.
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., et al. (2008). Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28, 5756–5761. doi: 10.1523/JNEUROSCI.1179-08.2008
Sekine, Y., Ouchi, Y., Takei, N., Yoshikawa, E., Nakamura, K., Futatsubashi, M., et al. (2006). Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry 63, 90–100. doi: 10.1001/archpsyc.63.1.90
Shapira, L., Ayalon, S., and Brenner, T. (2002). Effects of Porphyromonas gingivalis on the central nervous system: activation of glial cells and exacerbation of experimental autoimmune encephalomyelitis. J. Periodontol. 73, 511–516. doi: 10.1902/jop.2002.73.5.511
Sharma, H. S., and Kiyatkin, E. A. (2009). Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J. Chem. Neuroanat. 37, 18–32. doi: 10.1016/j.jchemneu.2008.08.002
Sharma, H. S., Sjoquist, P. O., and Ali, S. F. (2007). Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr. Pharm. Des. 13, 1903–1923. doi: 10.2174/138161207780858375
Sharp, C. D., Houghton, J., Elrod, J. W., Warren, A., Jackson, T. H. T., Jawahar, A., et al. (2005). N-methyl-D-aspartate receptor activation in human cerebral endothelium promotes intracellular oxidant stress. Am. J. Physiol. Heart Circ. Physiol. 288, H1893–H1899. doi: 10.1152/ajpheart.01110.2003
Shiu, C., Barbier, E., Di Cello, F., Choi, H. J., and Stins, M. (2007). HIV-1 gp120 as well as alcohol affect blood-brain barrier permeability and stress fiber formation: involvement of reactive oxygen species. Alcohol. Clin. Exp. Res. 31, 130–137. doi: 10.1111/j.1530-0277.2006.00271.x
Sonsalla, P. K., Riordan, D. E., and Heikkila, R. E. (1991). Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256, 506–512.
Stephans, S. E., Whittingham, T. S., Douglas, A. J., Lust, W. D., and Yamamoto, B. K. (1998). Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum. J. Neurochem. 71, 613–621. doi: 10.1046/j.1471-4159.1998.71020613.x
Thomas, D. M., Dowgiert, J., Geddes, T. J., Francescutti-Verbeem, D., Liu, X., and Kuhn, D. M. (2004a). Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367, 349–354. doi: 10.1016/j.neulet.2004.06.065
Thomas, D. M., Francescutti-Verbeem, D. M., Liu, X., and Kuhn, D. M. (2004b). Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment–an oligonucleotide microarray approach. J. Neurochem. 88, 380–393. doi: 10.1046/j.1471-4159.2003.02182.x
Thomas, D. M., Walker, P. D., Benjamins, J. A., Geddes, T. J., and Kuhn, D. M. (2004c). Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311, 1–7. doi: 10.1124/jpet.104.070961
Toborek, M., Lee, Y. W., Pu, H., Malecki, A., Flora, G., Garrido, R., et al. (2003). HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J. Neurochem. 84, 169–179. doi: 10.1046/j.1471-4159.2003.01543.x
Van De Haar, H. J., Burgmans, S., Hofman, P. A., Verhey, F. R., Jansen, J. F., and Backes, W. H. (2014). Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci. Biobehav. Rev. 49C, 71–81. doi: 10.1016/j.neubiorev.2014.11.022
Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., et al. (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21, 9414–9418.
Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., et al. (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158, 377–382. doi: 10.1176/appi.ajp.158.3.377
Wagner, G. C., Carelli, R. M., and Jarvis, M. F. (1985). Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res. Commun. Chem. Pathol. Pharmacol. 47, 221–228.
Wagner, G. C., Ricaurte, G. A., Seiden, L. S., Schuster, C. R., Miller, R. J., and Westley, J. (1980). Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181, 151–160. doi: 10.1016/0006-8993(80)91265-2
Warren, M. W., Kobeissy, F. H., Liu, M. C., Hayes, R. L., Gold, M. S., and Wang, K. K. (2005). Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. Life Sci. 78, 301–309. doi: 10.1016/j.lfs.2005.04.058
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G., Anthony, R. M., et al. (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2, 699–703. doi: 10.1038/nm0696-699
Wolkowicz, P. E., Ku, D. D., Grenett, H. E., and Urthaler, F. (2002). Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway. Prostaglandins Other Lipid Mediat. 70, 91–105. doi: 10.1016/S0090-6980(02)00014-X
Xie, T., McCann, U. D., Kim, S., Yuan, J., and Ricaurte, G. A. (2000). Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J. Neurosci. 20, 7838–7845.
Yamaguchi, T., Kuraishi, Y., Minami, M., Nakai, S., Hirai, Y., and Satoh, M. (1991). Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. Neurosci. Lett. 128, 90–92. doi: 10.1016/0304-3940(91)90766-M
Yamamoto, M., Ramirez, S. H., Sato, S., Kiyota, T., Cerny, R. L., Kaibuchi, K., et al. (2008). Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am. J. Pathol. 172, 521–533. doi: 10.2353/ajpath.2008.070076
Yang, G. Y., Gong, C., Qin, Z., Liu, X. H., and Lorris Betz, A. (1999). Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. Brain Res. Mol. Brain Res. 69, 135–143. doi: 10.1016/S0169-328X(99)00007-8
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., and Rosenberg, G. A. (2007). Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697–709. doi: 10.1038/sj.jcbfm.9600375
Zehendner, C. M., Librizzi, L., Hedrich, J., Bauer, N. M., Angamo, E. A., De Curtis, M., et al. (2013). Moderate hypoxia followed by reoxygenation results in blood-brain barrier breakdown via oxidative stress-dependent tight-junction protein disruption. PLoS ONE 8:e82823. doi: 10.1371/journal.pone.0082823
Zeng, X., Asmaro, K., Ren, C., Gao, M., Peng, C., Ding, J. Y., et al. (2012). Acute ethanol treatment reduces blood-brain barrier dysfunction following ischemia/reperfusion injury. Brain Res. 1437, 127–133. doi: 10.1016/j.brainres.2011.12.012
Keywords: methamphetamine, blood-brain barrier, oxidative stress, glutamate, neuroinflammation, tight junction
Citation: Northrop NA and Yamamoto BK (2015) Methamphetamine effects on blood-brain barrier structure and function. Front. Neurosci. 9:69. doi: 10.3389/fnins.2015.00069
Received: 23 January 2015; Paper pending published: 06 February 2015;
Accepted: 17 February 2015; Published: 04 March 2015.
Edited by:Jacob Raber, Oregon Health and Science University, USA
Reviewed by:Habibeh Khoshbouei, Univeristy of Florida, USA
Eugene A. Kiyatkin, National Institute on Drug Abuse, USA
Copyright © 2015 Northrop and Yamamoto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bryan K. Yamamoto, Department of Neurosciences, University of Toledo College of Medicine, 3000 Arlington Ave., Mail Stop #1007, Toledo, OH, USA email@example.com